Fevertree Drinks Plc Q2 2026 Earnings Recap

Investors appeared disappointed by the outlook and execution risk despite first-half growth, sending Fever-Tree shares down 3.6% after the results. The transcript highlights improving U.S. momentum, but the reaction suggests this was insufficient to offset concern around the pace and durability of growth.

Key Takeaways

• Brand revenue rose 8% at constant currency, with the U.S. up 11%, Europe up 10%, and the U.K. returning to growth.
• U.S. off-trade sales growth accelerated from 6% in Q1 to 11% in Q2 and 16% through July and August, supported by the Molson Coors partnership; management cautioned that it remains early.
• Adjusted EBITDA margin improved 20 basis points to 10.9%, while normalized EPS increased 5%.
• The wider portfolio grew 13%, versus 3% growth for the core tonic range, and now represents nearly half of group sales—evidence of diversification but also a relatively slower core category.
• The company extended its share buyback by £60 million, supported by cash generation and its asset-light model.